Showing results (4951-4960 of 5,702) with videos related to

Sort By:
Pageof 571
The Oncologist|October 11, 2013
Treatment of dexamethasone-induced hiccup in chemotherapy patients by methylprednisolone rotationGyeong-Won Lee, Sung Yong Oh, Myoung Hee Kang, et al.
The Oncologist|October 19, 2013
Optimizing tyrosine kinase inhibitor therapy in gastrointestinal stromal tumors: exploring the benefits of continuous kinase suppressionAxel Le Cesne, Jean-Yves Blay, Peter Reichardt, et al.
The Oncologist|June 8, 2012
Administration of angiotensin-converting enzyme inhibitors and β-blockers during adjuvant trastuzumab chemotherapy for nonmetastatic breast cancer: marker of risk or cardioprotection in the real world?Stefano Oliva, Giovanni Cioffi, Silvia Frattini, et al.
The Oncologist|April 26, 2012
The risk for anemia with targeted therapies for solid tumorsSandro Barni, Mary Cabiddu, Paolo Guarneri, et al.
The Oncologist|April 26, 2012
Novel approaches of chemoradiotherapy in unresectable stage IIIA and stage IIIB non-small cell lung cancerThomas E Stinchcombe, Jeffrey A Bogart
The Oncologist|April 26, 2012
Tailored therapy in an unselected population of 91 elderly patients with DLBCL prospectively evaluated using a simplified CGAAttilio Olivieri, Guido Gini, Caterina Bocci, et al.
The Oncologist|May 31, 2012
Approval summary: imatinib mesylate for one or three years in the adjuvant treatment of gastrointestinal stromal tumorsMartin H Cohen, John R Johnson, Robert Justice, et al.
The Oncologist|May 31, 2012
Circulating tumor cell count is a prognostic factor in metastatic colorectal cancer patients receiving first-line chemotherapy plus bevacizumab: a Spanish Cooperative Group for the Treatment of Digestive Tumors studyJavier Sastre, M Luisa Maestro, Auxiliadora Gómez-España, et al.
The Oncologist|August 24, 2016
Metastatic Breast Cancer With ESR1 Mutation: Clinical Management Considerations From the Molecular and Precision Medicine (MAP) Tumor Board at Massachusetts General HospitalAditya Bardia, John A Iafrate, Tilak Sundaresan, et al.
The Oncologist|March 19, 2010
Drug pricing and value in oncologyPatricia M Danzon, Erin Taylor
Pageof 571